Clinical trials: Melanoma Stage III
Melanoma, Recurrent Melanoma
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
This phase I trial is studying the side effects and best dose of temsirolimus when given together with sorafenib and to see how well they work in treating patients with metastatic, recurrent, or unresectable melanoma.
- Conditions
- Melanoma, Recurrent Melanoma, Stage III Melanoma, Stage IV Melanoma
- Trial name
- NCT00349206
- Testing
- sorafenib tosylate, temsirolimus
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma
Approximately 40-60 % of cutaneous melanomas select for a mutation in a protein called BRAF which is part of a signaling pathway called the Mitogen Activated Protein Kinase (MAPK) pathway.
- Trial name
- NCT01942993
- Testing
- Vemurafenib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Philip Friedlander
Melanoma (Skin)
Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma
RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00091143
- Testing
- gp100 antigen, incomplete Freund's adjuvant, keyhole limpet hemocyanin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Providence Cancer Center, Earle A. Chiles Research Institute
Breast Cancer, Kidney Cancer
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Breast Cancer, Kidney Cancer, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00006126
- Testing
- busulfan, cyclophosphamide, etoposide
- Sponsor
- Northwestern University
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying two different regimens of vaccine therapy and comparing them to see how well they work in…
- Trial name
- NCT00086866
- Testing
- D1/3-MAGE-3-His fusion protein, SB-AS02B adjuvant, SB-AS15 adjuvant
- Where
- 21 sites in Belgium, France and 5 more
- Volunteers
- 165 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
This phase I/IIa trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens…
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma
- Trial name
- NCT02650986
- Testing
- Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Roswell Park Cancer Institute
Unresected Stage IIIb to IVM1c Melanoma
Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma
Expanded access of Talimogene Laherparepvec for subjects with unresected, stage IIIb to IVM1c Melanoma.
- Trial name
- NCT02147951
- Testing
- Talimogene Laherparepvec
- Where
- 24 sites in United States
- Sponsor
- Amgen
Melanoma
Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation
In this study, the investigator's want to find out if dabrafenib can stop stage IIIC melanoma from coming back after surgery.
- Trial name
- NCT01682213
- Testing
- Dabrafenib
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma (Skin)
Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
RATIONALE: Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer.
- Trial name
- NCT00991991
- Testing
- gene expression analysis, polymerase chain reaction, polymorphism analysis
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Case Comprehensive Cancer Center
Non-Small Cell Lung Cancer, Melanoma
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
The primary objective of the study is to assess the efficacy in terms of CNS-specific PFS of the combination of standard systemic treatment plus SRS vs.
- Trial name
- USZ-STRIKE (NCT05522660)
- Testing
- Stereotactic radiosurgery, Immune checkpoint inhibitor
- Where
- 15 sites in Italy, Netherlands and 3 more
- Volunteers
- 180 people
- Sponsor
- ETOP IBCSG Partners Foundation
Melanoma
A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma
A study with YM155 for the treatment of unresectable stage III or metastatic stage IV melanoma.
- Trial name
- NCT00281541
- Testing
- YM155
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- Astellas Pharma Inc
Melanoma
Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients
The goal of this clinical research study is to learn if temozolomide alone or given with pegylated interferon alpha-2b can help to control metastatic melanoma. Researchers also want to study the safety of these 2 treatments.
- Trial name
- NCT00525031
- Testing
- Temozolomide (TMZ), Pegylated Interferon Alpha-2b (PGI)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma (Skin)
CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery
RATIONALE: Biological therapies, such as CP-675,206, work in different ways to stimulate the immune system and stop tumor cells from growing. Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00090896
- Testing
- maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Melanoma, Complication
Early Complications After Axillary and Inguinal Lymph Node Dissection in Stage III Melanoma Patients
This prospective randomized non-inferiority study is designed to compare the rate and severity of complications after axillary and inguinal lymph node dissection in stage III melanoma patients in a study group where the drain is…
- Trial name
- NCT04680182
- Testing
- Suction drain
- Where
- Norway
- Volunteers
- 104 people
- Sponsor
- Oslo University Hospital
Malignant Melanoma
GM-CSF as Adjuvant Therapy of Melanoma
This is a pilot study to describe the immunological responses and clinical outcome associated with administration of recombinant human Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) as surgical adjuvant therapy in…
- Trial name
- NCT00350597
- Testing
- Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Northern California Melanoma Center
Metastatic, Stage III or Stage IV, Melanoma
Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma
This is a phase II clinical study for patients with metastatic (the cancer has spread to other parts of the body) melanoma. Patients will receive an infusion (given by vein) of autologous tumor infiltrating lymphocytes (TILs).
- Trial name
- NCT01883323
- Testing
- Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University Health Network, Toronto
Malignant Melanoma
Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
This is a Phase I, open-label, multicenter, pharmacokinetic study of MDX-010 in up to 90 evaluable subjects with surgically unresectable malignant melanoma.
- Trial name
- NCT00729950
- Testing
- MDX-010
- Where
- 4 sites in United States
- Volunteers
- 92 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
PET-CT in the Management of Patients With Stage III or IV Metastatic Melanoma
The goal of this clinical research study is to learn how often using a positron emission tomography-computed tomography (PET-CT) scan in addition to a standard computed tomography (CT) scan will change the surgical plan in…
- Trial name
- NCT00828126
- Testing
- PET-CT Scan
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- M.D. Anderson Cancer Center
Anxiety Disorder, Worry
Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors
This randomized clinical trial studies a cognitive-behavioral intervention to treat worry, uncertainty, and insomnia in cancer survivors.
- Conditions
- Anxiety Disorder, Worry, Uncertainty, Sleep Disorders
- Trial name
- FOCUS (NCT01929720)
- Testing
- Cognitive-behavioral therapy for worry, uncertainty & insomnia
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Bone Loss in Melanoma Survivors Receiving Immunotherapy
This study investigates the bone-related side effects caused by immunotherapy drugs such as nivolumab and pembrolizumab in patients with melanoma.
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
- Trial name
- NCT04516122
- Testing
- Biospecimen Collection, Dual X-ray Absorptiometry
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center